65047-18-9Relevant academic research and scientific papers
NADPH OXIDASE INHIBITORS AND USES THEREOF
-
, (2019/02/13)
This disclosure relates to compounds and methods of treating or preventing a Nox related disease or condition comprising administering to a subject in need thereof a Nox inhibitor or pharmaceutical compositions comprising a Nox inhibitor disclosed herein,
Design, synthesis, and biological evaluation of inhibitors of the NADPH oxidase, Nox4
Xu, Qian,Kulkarni, Amol A.,Sajith, Ayyiliath M.,Hussein, Dilbi,Brown, David,Güner, Osman F.,Reddy, M. Damoder,Watkins, E. Blake,Lassègue, Bernard,Griendling, Kathy K.,Bowen, J. Phillip
, p. 989 - 998 (2018/02/19)
NADPH oxidases (Nox enzymes) are critical mediators of both physiologic and pathophysiologic processes. Nox enzymes catalyze NADPH-dependent generation of reactive oxygen species (ROS), including superoxide and hydrogen peroxide. Until recently, Nox4 was proposed to be involved exclusively in normal physiologic functions. Compelling evidence, however, suggests that Nox4 plays a critical role in fibrosis, as well as a host of pathologies and diseases. These considerations led to a search for novel, small molecule inhibitors of this important enzyme. Ultimately, a series of novel tertiary sulfonylureas (23–25) was designed using pharmacophore modeling, synthesized, and evaluated for inhibition of Nox4-dependent signaling.
